血清HIF-1a与VEGF含量变化对诊断HCC介入治疗预后的影响

目的探讨血清缺氧诱导因子-1a(HIF-1a)与血管内皮生长因子(VEGF)的含量变化对原发性肝癌(HCC)介入治疗预后的影响。方法选取2013年1月~2015年4月在我院治疗的HCC患者159例,所有患者均行肝癌动脉灌注化疗栓塞术,检测术前及术后1周HIF-1a与VEGF水平。结果患者术后1周HIF-1a与VEGF分别为(180.04±52.30)pg/ml和(312.04±78.20)pg/ml,明显低于术前(P0.05);术前HIF-1a与VEGF含量与患者性别、年龄、肿瘤位置、肿瘤直径、HBs Ag及胞膜无关(P0.05);有门脉癌栓患者术前HIF-1a与VEGF含量分别为(201.38±78.99)pg/ml和(368.29±80.01)pg/ml,明显高于无门脉癌栓患者(P0.05);CR+PR组患者术后1周HIF-1a与VEGF含量分别为(190.36±60.03)pg/ml和(312.38±80.04)pg/ml,明显低于SD+PD患者(P0.05);Kanplan-Meier分析显示术后1周血清HIF-1a与VEGF含量对患者预后有影响。结论血清HIF-1a与VEGF可作为评价HCC介入治疗预后的指标,术后1周HIF-1a与VEGF较低者预后较好。     

血清血管内皮细胞生长因子与肝细胞癌临床关系的研究

目的检测肝细胞癌(HCC)经导管化疗栓塞(TACE)前血清血管内皮细胞生长因子(VEGF)水平,并研究其与HCC侵袭,特别是复发转移的关系. 资料与方法前瞻性对30例HCC患者分别于术前取外周静脉血采用酶联免疫夹心法(ELISA)定量测量血清VEGF水平,于TACE术后3个月评估患者肝癌复发转移发生情况,同时以20例健康男性作为对照组予以对照. 结果 (1)对照组20例血清VEGF水平为22.82±10.95ng/L;(2)30例HCC患者术前血清VEGF水平为154.47±90.17ng/L,与对照组比较有统计学意义(P=0.0001);(3)转移肝癌组患者术前的血清VEGF为211.06±112.11ng/L,显著高于非转移肝癌组患者(135.79±49.82ng/L,P＜0.05).追踪半年期间,血清VEGF高水平组(＞100ng/L)患者中74%再发;而血清VEGF低水平组(＜100ng/L)的患者中无1例再发. 结论血清VEGF高水平是对应的肿瘤组织高表达的结果,与TACE术后HCC复发转移发生有关,HCC患者在TACE术前的血清VEGF水平可以作为预测HCC患者介入后复发转移的生物学指标.     

肝细胞癌化疗栓塞后胰岛素样生长因子-2与转移关系的研究

目的前瞻性评估肝细胞癌(HCC)经导管化疗栓塞(TACE)前后血清胰岛素样生长因子(IGF-2)表达变化与转移的关系。方法采用ELISA法对62例HCC患者分别于TACE术前、术后4周测血清IGF-2值,术后6个月评估远处转移发生情况。结果62例HCC患者术前血清IGF-2值为(6.74±0.04)pg/ml,术后血清IGF-2值较术前增高(P<0.05)。在碘油分布不均匀及门静脉癌栓组中,血清IGF-2值增高。血清IGF-2升高者中,半年内有20例发生远处转移,而血清IGF-2值下降组仅2例。结论HCC患者TACE后血清IGF-2增加,与转移发生有关;IGF-2可以作为提示转移发生的监测指标。     

肝癌患者血浆血管内皮生长因子的表达及动脉化疗栓塞对其影响的初步研究

目的　研究血管内皮生长因子 (vascularendothelialgrowthfactor,VEGF)在肝细胞癌(hepatocellularcarcinoma ,HCC)患者血浆中的表达水平与肝癌临床病理特征间的关系及其在动脉化疗栓塞 (transarterialchemoembolization ,TACE)治疗前后的变化。方法　 4 5例临床诊断为HCC的患者 ,于TACE术前、术后 1、3、7d及 1个月抽血 ,用酶联免疫吸附测定法 (ELISA法 )定量检测血浆中VEGF水平 ,同时对 2 0例肝脏良性疾病患者及 17例健康人血浆中VEGF水平进行检测。结果　HCC组血浆VEGF表达水平明显高于肝脏良性疾病组 (P =0 0 0 6 )及健康对照组 (P =0 0 0 3)。血浆VEGF表达水平随HCC患者TNM分级的升高而逐步升高 (P =0 0 4 4 ) ,较高血浆VEGF表达见于肿瘤较大 (P =0 0 0 6 ) ,以及并发有门脉癌栓 (P =0 0 11)、远处转移 (P =0 0 17)或动 门脉瘘 (P =0 0 2 6 )的病人。血浆VEGF的水平与血小板水平弱相关 (r=0 312 ,P =0 0 38) ,与血清甲胎蛋白 (AFP)水平不相关 (r =0 0 6 8,P =0 6 5 8)。TACE术后 1d血浆VEGF水平明显升高 ,与术前相比差异有显著性意义 ;其后 3、7d逐渐下降 ,与术前相比差异无显著性意义。血浆VEGF变化率 (术后 1个月 /术前× 10 0 % )与患者碘油积聚 (rs=0 4 94 ,P =0 0 0 1)及病灶变     

肝癌患者血清及肿瘤组织VEGF的表达及意义

目的探讨肝癌患者血清及组织中VEGF的表达情况及其在预测肝癌侵袭和患者预后的意义。方法将64例手术切除肝细胞肝癌患者分为复发组(n=42)与未复发组(n=22),采用酶联免疫吸附和免疫组化方法检测患者的术前血清及标本中VEGF的表达情况,分析其与临床病理指标关系并进行复发风险多因素分析。结果血清VEGF的浓度为334.50±247.62pg/ml,明显高于健康对照组(P<0.01)。复发组血清VEGF浓度明显高于未复发组(P<0.05)。已复发组VEGF的阳性率为85.7%,未复发组为54.5%(P<0.05)。VEGF阴性组的1、2、3年无瘤生存率分别为81.3%、68.8%及62.5%,VEGF阳性组的分别为52.1%、33.3%及29.1%(P<0.01)。多因素分析表明术前播散结节、微转移灶及VEGF的表达水平是影响预后的危险因素。结论肝癌患者血清及肿瘤组织中VEGF的表达水平明显升高,与肝癌患者的术后复发相关,可预测患者的复发风险。     

原发性肝癌TACE前后血清VEGF与CT灌注参数间相关性的研究

目的 探讨原发性肝癌(HCC)患者TACE前后血清血管内皮生长因子(VEGF)水平和CT灌注参数之间的关系. 资料与方法 对17例HCC患者于TACE术前1天及术后7～10天测量血清VEGF水平,同时行CT灌注扫描,计算肝血流量(HBF)、肝动脉灌注分数(HAF),肝动脉灌注量(HAP)、门静脉灌注量(PVP). 结果 原发性肝癌TACE前后HBF、HAP差异有统计学意义,血清VEGF与HBF、HAF、HAP呈正相关. 结论 血清VEGF水平及CT灌注可帮助评价肝癌TACE疗效.     

血清nm23-H1水平对肝细胞肝癌TACE治疗预后的影响

目的 探讨肝细胞肝癌患者血清nm23-H1基因水平及其对TACE治疗预后的影响.方法 收集60例行TACE治疗的肝细胞肝癌患者血清,采用ELISA检测血清nm23-H1水平,并与12例正常对照组进行比较.回顾性分析所有患者的临床病理资料,对患者血清nm23-H1水平与临床资料进行相关性分析,用Kaplan-Meier生存曲线分析患者生存率,并用log等级检验比较.多因素分析方法评估血清nm23-H1水平及相关因素对预后的意义.结果 肝细胞肝癌患者血清nm23-H1平均水平为(126.4 ± 51.3)ng/ml,明显低于正常对照组的(228.3 ± 38. 9)ng/ml(P < 0. 01).患者血清nm23-H1水平与白蛋白水平呈负相关(r ＝ -0.256, P ＝ 0.048),而与患者年龄及血清AFP、ALT、AST、GGT、胆红素水平均无相关性.随访1周～ 83个月,中位随访时间为17.5个月.单因素分析显示肝外转移、门静脉瘤栓、动静脉瘘和血清AFP升高是预后不良的因素.多因素COX模型分析显示血清nm23-H1水平是影响生存的因素之一.结论 血清nm23-H1水平有可能作为肝细胞肝癌患者TACE治疗疗效观察及预后判断的有用指标.     

血清血管内皮生长因子及CT灌注与原发性肝癌栓塞化疗的相关性分析

目的 探讨原发性肝癌(HCC)患者栓塞前后血清血管内皮生长因子(VEGF)水平和CT灌注参数之间的关系.方法 对17例HCC患者于经导管动脉栓塞化疗(TACE)术前1 d、术后7～10 d分别采用酶联免疫吸附定量法测量血清VEGF水平,同时行CT灌注扫描,计算各函数图中肝血流量(HBF)、肝动脉灌注分数(HAF),肝动脉灌流量(HAP)、门静脉灌流量(FVP).结果 原发性肝癌栓塞前后的HBF、HAP存在显著差异,HAF、PVP、VEGF无显著差异.血清VEGF与HBF、HAF、HAP呈正相关,而与PVP无明显相关性.结论 血清VEGF水平及CT灌注对评价肝癌TACE疗效、指导治疗有重要价值.     

血清高迁移率组蛋白B1、可溶性晚期糖基化终末产物受体、脱氧核糖核酸酶与TACE早期疗效相关性研究

目的 探讨原发性肝癌患者血清高迁移率组蛋白B1(HMGBl)、人可溶性晚期糖基化终末产物(sRAGE)、脱氧核糖核酸酶(DNase)对TACE近期疗效的评估价值.方法 对收住的42例患者(共计56次TACE治疗)分别在TACE术前、术后24h采集外周静脉血标本,用ELISA法检测外周血清中HMGB1、sRAGE、DNase的表达水平.根据mRECIST标准进行TACE术后疗效评估,将完全缓解+部分缓解+疾病稳定的病例归为获益组,疾病进展者归为无效组.比较TACE术前、术后,获益组及无效组之间的血清HMGB1、sRAGE、Dnase的表达水平,并进行统计学分析.结果 TACE术前与术后24 h血清HMGB1、sRAGE、DNase表达水平比较差异有显著统计学意义(P=0.003,P=000,P=0.001),且术后较术前呈升高趋势.56例次TACE中,24例次为稳定(SD),2例次部分缓解(PR),30例次为肿瘤进展(PD),将SD和PR患者归为获益组(n=26),PD患者为无效组(n=30).在TACE术前,获益组与无效组血清HMGB1、DNase表达水平比较差异无统计意义(P=0.395,P=0.091);在TACE术后24 h,血清HMGB1、DNase在获益组和无效组对比差异也无统计学意义(P=0.354,P=0.182).而sRAGE在获益组与无效组之间的表达水平在术前差异无统计学意义(P=0.143),而在术后24h,两组间sRAGE表达水平差异有统计学意义(P=0.030).结论 ①TACE术后血清HMGB1、sRAGE、DNase表达水平较术前升高;②中晚期肝癌患者外周血清中sRAGE与TACE疗效相关,可以作为TACE治疗肝癌疗效早期评估的指标.     

肝细胞生长因子及其c-Met受体表达与原发性小肝癌术后复发关系的初步研究

目的　探讨原发性小肝癌 (SHCC)切除术后血清肝细胞生长因子 (HGF)水平和癌组织中c Met受体表达与术后复发的关系。方法　采用ELISA对手术前后血清HGF浓度变化进行检测 ,并利用Western、Northern印迹杂交方法 ,测定肿瘤与非肿瘤组织内c Met蛋白表达量。结果　术前血清HGF浓度为 0 64± 0 15ng/ml,术后 3天为 1 41±0 2 8ng/ml,二者差异有显著性意义 (P <0 0 0 1)。术后 3天血清HGF浓度是术前的 2 3 2± 0 5 5倍。术后HGF的增长倍数与肿瘤组织内c Met蛋白的过度表达在术后复发与未复发者中差别有显著性意义(P <0 0 5 ) ,两年内复发者明显高于两年后复发及未复发者。结论　SHCC切除术后血清HGF水平明显增高 ,肿瘤组织本身c Met蛋白过度表达 ,可能与SHCC术后早期复发有关     

Knee injury and Osteoarthritis Outcome Score (KOOS) - validation of a Swedish version

The Knee injury and Osteoarthritis Outcome Score (KOOS) is a self-administered instrument measuring outcome after knee injury at impairment, disability, and handicap level in five subscales. Reliability, validity, and responsiveness of a Swedish version was assessed in 142 patients who underwent arthroscopy because of injury to the menisci, anterior cruciate ligament, or cartilage of the knee. The clinimetric properties were found to be good and comparable to the American version of the KOOS. Comparison to the Short Form-36 and the Lysholm knee scoring scale revealed expected correlations and construct validity. Item by item, symptoms and functional limitations were compared between diagnostic groups. High responsiveness was found three months after arthroscopic partial meniscectomy for all subscales but Activities of Daily Living.     

The acutely limping child

Acute limping may be the result of multiple pathologies in children. The differential diagnosis varies based on the age of the child. Irrespective of age, the initial imaging work-up includes AP and frog leg radiographs of the pelvis and ultrasound; MRI may sometimes be helpful. In children less than 3 years, infections and trauma are most frequent. MRI is the imaging modality of choice when osteomyelitis is clinically suspected. Between the ages of 3 and 10 years, transient synovitis of the hip and Legg-Calvé-Perthes disease are main considerations but infection, inflammation and focal bony lesions are also considered. In children over 10 years, slipped capital femoral epiphysis also is considered.     

High Intensity Interval Training:New Insights

KEY POINTS ·High-intensity interval training(HIT)is characterized by repeated sessions of relatively brief，intermittent exercise.often performed with an“a11 out”effort or at an intensity close to that which elicits peak oxygen uptake(i.e.，≥90%of VO2 peak).     

Endovascular management of carotid-cavernous fistulas

Objective To investigate endovascular treatment of traumatic direct carotid-cavernous fistulas （CCF） and their complications such as pseudoaneurysms. Methods： Over a five-year period, 22 patients with traumatic direct CCFs were treated endovascularly in our institution. Thirteen patients were treated once with the result of CCF occluded, 8 twice and 1 three times. Treatment modalities included balloon occlusion of the CCF, sacrifice of the ipsilateral internal carotid artery with detachable balloon, coll embolization of the cavernous sinus and secondary pseudoaneurysms, and covered-stem management of the pseudoaneurysms. Results All the direct CCFs were successfully managed endovascularly. Four patients developed a pseudoaneurysm after the occlusion of the CCF with an incidence of pseudoaneurysm formation of 18.2% （4/22）. A total number of 8 patients experienced permanent occlusion of the ICA with a rate of ICA occlusion reaching 36.4% （8/22）. Followed up through telephone consultation from 6 months to 5 years, all did well with no recurrence of CCF symptoms and signs. Conclusion Traumatic direct CCFs can be successfully managed with endovascular means. The pseudoaneurysms secondary to the occlusion of the CCFs can be occluded with stent-assisted coiling and implantation of covered stents.     

Developmental validation of the PowerPlex(®) ESI 16 and PowerPlex(®) ESI 17 Systems: STR multiplexes for the new European standard

In response to the ENFSI and EDNAP groups’ call for new STR multiplexes for Europe, Promega^® developed a suite of four new DNA profiling kits. This paper describes the developmental validation study performed on the PowerPlex^® ESI 16 (European Standard Investigator 16) and the PowerPlex^® ESI 17 Systems. The PowerPlex^® ESI 16 System combines the 11 loci compatible with the UK National DNA Database^®, contained within the AmpFlSTR^® SGM Plus^® PCR Amplification Kit, with five additional loci: D2S441, D10S1248, D22S1045, D1S1656 and D12S391. The multiplex was designed to reduce the amplicon size of the loci found in the AmpFlSTR^® SGM Plus^® kit. This design facilitates increased robustness and amplification success for the loci used in the national DNA databases created in many countries, when analyzing degraded DNA samples. The PowerPlex^® ESI 17 System amplifies the same loci as the PowerPlex^® ESI 16 System, but with the addition of a primer pair for the SE33 locus. Tests were designed to address the developmental validation guidelines issued by the Scientific Working Group on DNA Analysis Methods (SWGDAM), and those of the DNA Advisory Board (DAB). Samples processed include DNA mixtures, PCR reactions spiked with inhibitors, a sensitivity series, and 306 United Kingdom donor samples to determine concordance with data generated with the AmpFlSTR^® SGM Plus^® kit. Allele frequencies from 242 white Caucasian samples collected in the United Kingdom are also presented. The PowerPlex^® ESI 16 and ESI 17 Systems are robust and sensitive tools, suitable for the analysis of forensic DNA samples. Full profiles were routinely observed with 62.5 pg of a fully heterozygous single source DNA template. This high level of sensitivity was found to impact on mixture analyses, where 54–86% of unique minor contributor alleles were routinely observed in a 1:19 mixture ratio. Improved sensitivity combined with the robustness afforded by smaller amplicons has substantially improved the quantity of data obtained from degraded samples, and the improved chemistry confers exceptional tolerance to high levels of laboratory prepared inhibitors.     

Bronchial stump fistula :treatment with covered retrievable hinged metallic stents-preliminary clinical experience

Objective To evaluate the preliminaily clinical efficacy and retrievability of a retrievable hinged covered metallic stent in the treatment of the bronchial stump fistula （BSF）. Methods Between April 2003 and March 2005, 8 patients with bronchial stump fistula after pneumonectomy or lobectomy were treated with two types （A and B） of retrievable hinged covered metallic stents. Type A stent was placed in 6 patients and type B in 2 under fluoroscopic guidance. The stent was removed with a retrieval set when BSF was healed or complications occurred. Results Stent placement in the bronchial tree was technically successful in all patients, without procedure-related complications. Immediate closure of the BSF was achieved in all patients after the procedure. Stents were removed from all patients but one. Removal of the stents was difficult in two patients due to tissue hyperplasia. Patients were followed up for 6 - 21 months. Placement of the stents remained stable in all patients except one due to severe cough. Permanent closure of BSF was achieved in 7 （87.5%） of 8 patients. Conclusion Use of a retrievable hinged covered expandable metallic stent is a simple, safe, and effective procedure for closure of the BSF. Retrieval of the stent seems to be feasible. （J Intervent Radiol, 2007, 16： 253-257）